Price
No data yet.
Social Signal Score
Analyst Ratings
29 analystsRevenue
$8.82B+16.23%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Luke Victor Miels
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- Employees
- 66,841
- Beta
- 0.28
- Country
- GB
- Piotroski score
- 8 / 9 (Strong)
- Altman Z-score
- 1.78
Financials
Revenue
$8.82B+16.2%Net Income
$1.53B+495.7%EBITDA
$3.28B+169.0%Free Cash Flow
$2.41B+8.2%EPS (diluted)
$0.76+484.6%Shares Outstanding (diluted)
2.04B+3.6%Operating Expenses
$4.24BCash & Debt
$2.98BReturn of Capital
$680.96MRevenue by Segment (annual)
$8.96BDividend per Share
$0.45Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $32.67B | $5.72B | $2.82 |
| 2024 | $31.38B | $2.58B | $1.26 |
| 2023 | $30.33B | $4.93B | $2.43 |
| 2022 | $29.32B | $14.96B | $7.43 |
| 2021 | $24.70B | $4.38B | $2.74 |
| 2020 | $24.35B | $5.75B | $2.88 |
| 2019 | $33.75B | $4.64B | $2.34 |
| 2018 | $30.82B | $3.62B | $1.84 |
| 2017 | $30.19B | $1.53B | $0.78 |
| 2016 | $27.89B | $912.00M | $0.48 |
| 2015 | $23.92B | $8.42B | $4.36 |
| 2014 | $23.01B | $2.76B | $1.44 |
| 2013 | $26.50B | $5.44B | $2.82 |
| 2012 | $26.43B | $4.50B | $2.30 |
Valuation
Project earnings forward and see what return today's price implies.
Seeded from GSK's reported EPS growth of 1.6% a year over 13 years.
- EPS in 5 years
- $3.06
- Implied price
- $39.72
- Return from $47.76
- -3.6% a year
To earn 15.0% a year on these assumptions you'd need to buy at $19.75 — -58.7% below today's price.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 9 | 11 | 13 | 15 | 17 |
|---|---|---|---|---|---|
| -8.4% | -19.3% | -16.0% | -13.1% | -10.6% | -8.3% |
| -3.4% | -14.9% | -11.4% | -8.4% | -5.7% | -3.3% |
| 1.6% | -10.5% | -6.8% | -3.6% | -0.8% | 1.7% |
| 6.6% | -6.0% | -2.2% | 1.1% | 4.1% | 6.7% |
| 11.6% | -1.6% | 2.4% | 5.9% | 8.9% | 11.7% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
55+10.00%Social Signal Score
Mentions (56)
- Newszacks.com·4d ago·Neutral
GSK Wins FDA Approval for Nuvalent-Acquired Nelkarmi in Lung Cancer GSK gains FDA accelerated approval for Nelkarmi in advanced ALK-positive lung cancer, strengthening its oncology portfolio.
View source ↗ - Newsreuters.com·5d ago·Negative
FDA grants accelerated approval to GSK's lung cancer drug FDA grants accelerated approval to GSK's lung cancer drug
View source ↗ - Newsmarketbeat.com·5d ago·Negative
GSK Targets £40 Billion in Sales as HIV Patent Cliff Looms GSK NYSE: GSK expects to grow through the loss of patent protection for key HIV medicines, relying on a pipeline of new treatments, an expanding oncology business and continued dealmaking, President of Business Development David Redfern said at the Jefferies Healthcare Conference.
View source ↗ - Newsfool.com·5d ago·Positive
GSK: 3 Key Takeaways for Long-Term Investors GSK started 18 phase 3 clinical trials in 2026. Specialty medicine sales grew 15% in the third quarter.
View source ↗ - Newsmarketbeat.com·13d ago·Positive
GSK Accelerates Late-Stage Studies as It Targets COPD and Long-Acting Respiratory Treatments GSK NYSE: GSK is advancing a portfolio of long-acting medicines and combination treatments for respiratory and inflammatory diseases, with a particular focus on chronic obstructive pulmonary disease, a senior research executive said at Guggenheim's Healthcare Innovation Conference.
View source ↗ - Newsreuters.com·16d ago·Neutral
GSK, Moderna settle patent dispute over Moderna COVID, RSV shots GSK, Moderna settle patent dispute over Moderna COVID, RSV shots
View source ↗ - Newsnypost.com·18d ago·Positive
HP taps Emma Walmsley, ex-GSK chief and Microsoft board member, as CEO HP, like peers Dell Technologies, Apple and Lenovo, is caught in a global memory chip squeeze.
View source ↗ - Newsseekingalpha.com·23d ago·Neutral
GSK: The Gas Pedal Is Still Down, But Bumps Ahead Despite the Q3 disappointments, I maintain my Buy rating, as strong Specialty Medicines growth and improving pipeline momentum continue to support GSK's long-term ambitions. Specialty Medicines revenue rose 14%, helping offset weakness in Vaccines. HIV, Oncology and Respiratory remain key drivers of GSK's future growth. The vaccine business underperformed, with Shingrix and Arexvy missing expectations; management attributes this to China inventor…
View source ↗ - Newszacks.com·24d ago·Positive
GSK vs. Moderna: Which Large-Cap Biotech Stock Offers More Growth? GSK's Specialty Medicines growth, deep pipeline and dividend offer a compelling case against MRNA's oncology potential and premium valuation.
View source ↗ - Newsseekingalpha.com·25d ago·Neutral
GSK plc (GSK) Q3 2026 Earnings Call Transcript GSK plc ( GSK ) Q3 2026 Earnings Call October 28, 2026 8:00 AM EDT Company Participants Jeff McLaughlin - VP of Investor Relations & Interim Head of Investor Relations Luke Miels - CEO & Director Tony Wood - Chief Scientific Officer and Head of R&D Nina Mojas - President of Global Product Strategy Julie Brown - CFO & Executive Director David Redfern - President of Corporate Development Conference Call Participants James Gordon - Barclays Bank PLC, R…
View source ↗ - Newsmarketbeat.com·25d ago·Neutral
What GSK (GSK) Said on Its Q3 Earnings Call GSK NYSE: GSK reported third-quarter sales growth of 5% at constant exchange rates to £8.9 billion, supported by specialty medicines, new product launches and oncology growth. Core operating profit increased 5%, while core earnings per share rose 1%.
View source ↗ - Newszacks.com·25d ago·Positive
GSK Q3 Earnings Top Mark, Stock Down on Soft Vaccines Sales GSK's Q3 earnings beat estimates as HIV, oncology and respiratory medicines drive revenue growth, while declining vaccine sales weigh on shares.
View source ↗ - Newszacks.com·25d ago·Positive
GSK (GSK) Q3 Earnings and Revenues Beat Estimates GSK (GSK) came out with quarterly earnings of $1.47 per share, beating the Zacks Consensus Estimate of $1.4 per share. This compares to earnings of $1.48 per share a year ago.
View source ↗ - Newswsj.com·25d ago·Negative
GSK Sales Get Boost From Specialty Medicines The U.K. drugmaker's strength in the segment allowed it to offset a declining vaccines revenue and a flat performance in general medicines.
View source ↗ - Newsreuters.com·25d ago·Neutral
GSK beats third-quarter profit estimates, keeps annual targets GSK beat third-quarter sales and profit expectations on Wednesday, helped by demand for specialty medicines, suggesting CEO Luke Miels' efforts to accelerate growth and prepare the drugmaker for
View source ↗ - Newsseekingalpha.com·26d ago·Positive
GSK plc (GSK) Presents at 2026 European Society for Medical Oncology (ESMO) Annual Congress Transcript GSK plc (GSK) Presents at 2026 European Society for Medical Oncology (ESMO) Annual Congress Transcript
View source ↗ - Newsmarketbeat.com·26d ago·Negative
GSK Showcases Strong Oncology Pipeline Data at ESMO Investor Update GSK NYSE: GSK highlighted clinical data across its oncology pipeline at the European Society for Medical Oncology meeting, including updates for its B7-H3 antibody-drug conjugate ris-rez, B7-H4 ADC mo-rez, PD-1 therapy dostarlimab and ROS1 inhibitor JIDEYTRO.
View source ↗ - Newsreuters.com·26d ago·Negative
GSK to nearly double cancer drugs in trials, WSJ reports GSK expects to nearly double the number of cancer medicines it is testing in clinical trials next year, the Wall Street Journal reported on Tuesday, citing an interview with a scientist
View source ↗ - Newswsj.com·26d ago·Negative
GSK Sees Cancer-Drug Pipeline Nearly Doubling Next Year After Dealmaking Spree EXCLUSIVE: The U.K. drugmaker currently has five approved cancer medicines and a clinical-stage portfolio of about 15 assets.
View source ↗ - News247wallst.com·29d ago·Negative
Can Specialty Meds Offset GSK's $2.2B Legal Charges and Sizzling R&D Setbacks on Oct. 28? GSK (NYSE:GSK | GSK Price Prediction) reports third-quarter results on October 28. A $2.
View source ↗ - Newsproactiveinvestors.com·32d ago·Negative
GSK hepatitis B drug approval supports £2.2bn sales forecast, Jefferies says Jefferies has reiterated its 'buy' rating on GSK PLC (LSE:GSK, NYSE:GSK), the pharmaceutical company, with a 2,500p price target after US regulators approved its hepatitis B treatment, Hibsago. The target represents a potential upside of 34% from the 1,868.5p closing price used in the broker's 21 October research note.
View source ↗ - Newsproactiveinvestors.com·34d ago·Negative
Jefferies backs GSK with 2,500p target after positive lung cancer drug results Jefferies rates GSK PLC (LSE:GSK, NYSE:GSK), the FTSE 100 pharmaceutical company, 'buy' with a 2,500p price target, implying 34% upside from Friday's close of 1,862.50p, after global trial results for its experimental cancer drug ris-rez showed a 61% tumour response rate. The EMBOLD study in extensive-stage small-cell lung cancer showed an objective response rate of 61% among patients receiving 8mg/kg, with 11 of 18 r…
View source ↗ - Newsproactiveinvestors.com·34d ago·Negative
GSK lung cancer drug shows 61% response rate in early global trial GSK PLC (LSE:GSK, NYSE:GSK) said its experimental lung cancer treatment risvutatug rezetecan produced a 61% confirmed response rate at the higher dose tested in an early-stage global trial of patients with relapsed extensive-stage small cell lung cancer. The FTSE 100 pharmaceutical group said 11 of 18 evaluable patients receiving an 8 milligram per kilogram dose responded to treatment, compared with seven of 22 patients, or 32%, …
View source ↗ - Newsseekingalpha.com·39d ago·Positive
GSK: Maintaining Strong Buy For LAI HIV Sales Growth And Further Oncology Expansion GSK plc demonstrates strong oncology pipeline momentum, highlighted by Mo-Rez's phase 1 success in platinum-resistant ovarian and endometrial cancers. Mo-Rez's impressive response rates support five global pivotal phase 3 trials planned for 2026, underscoring GSK's late-stage oncology expansion. GSK's ViiV Healthcare reports Cabenuva's superior viral suppression in HIV, and the company advances key acquisitions a…
View source ↗ - Newsreuters.com·39d ago·Neutral
GSK to cut up to 1,217 jobs in Belgium, L'Echo says GSK to cut up to 1,217 jobs in Belgium, L'Echo says
View source ↗ - Newsproactiveinvestors.com·40d ago·Negative
GSK third quarter likely to be in line as RBC sees vaccine headwinds offset by HIV strength GSK PLC (LSE:GSK, NYSE:GSK) is expected to deliver a broadly in-line third quarter as weaker vaccine sales are offset by strength in HIV treatments and respiratory drug Nucala, according to RBC Capital Markets. The broker reiterated its Sector Perform rating and 1,975p price target ahead of GSK's results on 28 October, compared with a share price of 1,771p when the note was published.
View source ↗ - Newszacks.com·41d ago·Negative
Is the Options Market Predicting a Spike in GSK Plc Stock? Investors need to pay close attention to GSK stock based on the movements in the options market lately.
View source ↗ - Newsreuters.com·44d ago·Neutral
Pennsylvania says GSK to invest more than $800 million in biopharma hub, create 300 jobs GSK will invest more than $800 million to expand its Upper Merion, Pennsylvania site into a new biopharmaceutical manufacturing and research hub, creating more than 300 jobs over the next five years, Pennsylvania Governor Josh Shapiro's office said on Friday.
View source ↗ - Newsbusinesswire.com·44d ago·Neutral
Chai Discovery Announces Collaboration with GSK Following Successful Wet-Lab Evaluation SAN FRANCISCO--(BUSINESS WIRE)--Chai Discovery, the AI company building a computer-aided design suite for molecules, today announced a collaboration with GSK.
View source ↗ - Newsprnewswire.com·45d ago·Positive
Viola Davis partners with GSK to educate adults 50 and older about their shingles risk For the first time, Viola Davis shares her experience with shingles Viola encourages adults 50 years and older to prioritize their health and have candid conversations about increased risks that come with aging The partnership is part of GSK's new national "Shingles, actually" disease education campaign PHILADELPHIA, Oct. 8, 2026 /PRNewswire/ -- GSK plc (LSE/NYSE: GSK) today announced a partnership with award-…
View source ↗ - Newsseekingalpha.com·46d ago·Positive
GSK: The Gas Pedal Is Finally Down GSK is accelerating its strategic transformation under new CEO Luke Miels, emphasizing M&A, pipeline expansion, and proactive HIV franchise management. At approximately 7x NTM EV/EBITDA, GSK offers an attractive risk/reward for investors willing to accept execution risk, meriting a Buy rating. The company is targeting over 20 Phase III starts in 2026, reinvesting GBP 1.9bn annual cost savings into R&D and M&A to offset the upcoming HIV patent cliff.
View source ↗ - Newsglobenewswire.com·53d ago·Positive
Wave Life Sciences Announces GSK's Selection of siRNA program to Transition to GSK for Further Development Candidate selected by GSK utilizes Wave's best-in-class SpiNA design siRNA and triggers a milestone payment to Wave; three additional collaboration programs advancing
View source ↗ - Newszacks.com·54d ago·Negative
GSK vs. SNY: Which Europe-Based Pharma Stock Has More Potential? GSK and Sanofi offer distinct growth drivers, but stronger earnings estimates, Dupixent momentum and a lower valuation are putting one European drugmaker in focus.
View source ↗ - Newszacks.com·55d ago·Negative
Merck, Daiichi Withdraw FDA Filing for Lung Cancer Therapy MRK and Daiichi withdraw an FDA filing for ifinatamab deruxtecan after data falls short, while late-stage studies continue.
View source ↗ - Newsbusinesswire.com·55d ago·Neutral
AN2 Therapeutics Announces Extension of Funding for Tuberculosis Research Collaboration with GSK MENLO PARK, Calif.--(BUSINESS WIRE)--AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage pharmaceutical company focused on the discovery and development of small molecule therapeutics derived from its boron chemistry platform, today announced that the Gates Foundation has awarded an extension of funding to support AN2 Therapeutics' research activities under its ongoing tuberculosis (TB) research …
View source ↗ - Newsseekingalpha.com·60d ago·Positive
GSK plc (GSK) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript GSK plc (GSK) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 3rd Annual Healthcare Forum Transcript
View source ↗ - Newsmarketbeat.com·60d ago·Neutral
GSK Bets on Long-Acting Biologics and AI to Reshape Respiratory Care GSK NYSE: GSK is advancing a respiratory and immunology pipeline centered on longer-acting biologics, more targeted patient selection and combination approaches, according to Kaivan Khavandi, the company's senior vice president and global head of Translational and Development Sciences.
View source ↗ - Newsmarketbeat.com·60d ago·Neutral
GSK Targets £40B Sales as Oncology Push and £1.9B Savings Plan Take Shape GSK NYSE: GSK Chief Financial Officer Julie Brown outlined the company's growth strategy, launch priorities and cost-savings plans during a discussion with Bank of America analyst Sachin Jain following the company's recent capital markets day.
View source ↗ - Newsmarketbeat.com·67d ago·Neutral
GSK Targets Oncology Growth With Lung, Prostate and Gynecologic Cancer Pipeline GSK NYSE: GSK is pursuing a focused oncology expansion built around hematologic malignancies, gynecologic cancers, lung cancer, gastrointestinal cancers and prostate cancer, with a combination of internal research and business development, according to Hesham Abdullah, the company's senior vice president and global head of oncology research and development.
View source ↗ - Newsseekingalpha.com·68d ago·Positive
GSK plc (GSK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript GSK plc (GSK) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
View source ↗ - Newsreuters.com·68d ago·Negative
GSK strikes up to $750 million deal for cancer-targeting drug GSK said on Tuesday it had agreed a deal worth up to $750 million to buy a trispecific T cell-engager (TCE), a drug designed to help T-cells target cancer, from China-based biotechnology firm Chimagen Biosciences.
View source ↗ - Newszacks.com·69d ago·Positive
GSK Presents Jideytro Data for Potential Use in First-Line NSCLC GSK's Jideytro delivers strong first-line NSCLC results, with high response rates and durable disease control supporting a planned FDA filing.
View source ↗ - Newsmarketbeat.com·70d ago·Neutral
GSK Targets £1.9B Savings to Fuel Pipeline, Navigate HIV Patent Cliff GSK NYSE: GSK is accelerating investment in research and development, expanding its late-stage pipeline and targeting cost savings to support product launches while maintaining profitability through upcoming HIV patent expirations, Chief Financial Officer Julie Brown said during a company discussion.
View source ↗ - Newsreuters.com·72d ago·Neutral
GSK to shut vaccine factory in Germany, putting 641 jobs at risk GSK said on Friday it will be shutting down a vaccine factory in Dresden, Germany, which its website showed produces flu and hepatitis shots, in the summer of 2027.
View source ↗ - Newszacks.com·73d ago·Neutral
GSK's Specialty Medicines Drive Growth Amid Looming HIV Patent Cliff GSK's Specialty Medicines are driving growth, but an approaching HIV patent cliff is pushing the company to accelerate its pipeline.
View source ↗ - Newsseekingalpha.com·74d ago·Positive
GSK plc (GSK) Presents at Bernstein's 23rd Annual Pan-European Strategic Decisions Conference Transcript GSK plc (GSK) Presents at Bernstein's 23rd Annual Pan-European Strategic Decisions Conference Transcript
View source ↗ - Newsproactiveinvestors.co.uk·79d ago·Neutral
GSK's mRNA flu vaccine data closely tracks Moderna's, Deutsche Bank says GSK PLC's (LSE:GSK, NYSE:GSK) experimental mRNA flu vaccine produced data that closely resemble Moderna's own candidate, according to Deutsche Bank. Analyst Emmanuel Papadakis reviewed detailed phase II results GSK presented at the OPTIONS XIII Conference for the Control of Influenza last weekend.
View source ↗ - Newsproactiveinvestors.co.uk·80d ago·Positive
Panmure and Cavendish reiterate buy on Hutchmed after GSK deal Hutchmed (China) Ltd (AIM:HCM, NASDAQ:HCM, HKG:0013, FRA:H7T2) won ringing endorsements from City brokers on Thursday after securing a blockbuster licensing agreement with GSK PLC (LSE:GSK, NYSE:GSK), exposing what analysts regard as a deep valuation disconnect. The shares leapt 15% to 205.84p as Cavendish and Panmure Liberum reiterated their respective 'buy' ratings, arguing that the market continues to overlook the biotech's expand…
View source ↗ - Newszacks.com·81d ago·Positive
GSK to Advance mRNA Influenza Vaccine Into Phase III Development GSK to advance its mRNA flu vaccine into phase III after phase II study has shown stronger immune responses and good tolerability.
View source ↗ - Newszacks.com·82d ago·Positive
GSK Stock Down 14% in Six Months: Time to Buy, Hold or Exit? GSK's shares are down 14% in six months, but strong Specialty Medicines growth and a robust pipeline may support long-term gains.
View source ↗ - Newsreuters.com·82d ago·Positive
GSK to advance mRNA flu vaccine to late-stage trial GSK said on Tuesday it will advance its mRNA-based seasonal influenza vaccine candidate into a late-stage trial after mid-stage data showed it generated stronger immune responses than currently approved standard- and high-dose shots.
View source ↗ - Newsseekingalpha.com·87d ago·Neutral
GSK: Still One Of My Top Healthcare Picks H2 2026/Q1 2027 will be rich in catalysts. From the potential FDA approval of bepirovirsen, with a target action date of October 26, for the treatment of chronic hepatitis B, to the Phase 3 OCEAN study results. By the way, Hibsago [bepirovirsen] was approved by Japan's Ministry of Health, Labour, and Welfare on August 24.
View source ↗ - Newszacks.com·90d ago·Neutral
GSK's sBLA for Jemperli Gets FDA Priority Tag in Rectal Cancer GSK's Jemperli gets FDA priority review for dMMR/MSI-H rectal cancer with a decision due in February 2027, while Hibsago wins Japan approval in CHB.
View source ↗ - Newsreuters.com·90d ago·Negative
GSK scores regulatory wins for chronic hepatitis B drug, cancer therapy GSK said on Monday its experimental chronic hepatitis B drug received its first global approval in Japan, and a key cancer therapy was granted a priority U.S. regulatory review as a possible rectal cancer treatment.
View source ↗ - Newsproactiveinvestors.co.uk·94d ago·Negative
GSK shares kept at neutral by Citi as unproven phase III pipeline curbs long-term growth GSK PLC (LSE:GSK, NYSE:GSK) got a grudging nod from Citi on Thursday, as the investment bank lifted its earnings forecasts for the drugmaker but stopped well short of a buy call. The shares edged up 0.31% to 1,922p as Citi kept its 'neutral' rating, tweaking its model after GSK's Accelerate Growth event and second-quarter results.
View source ↗ - Newscnbc.com·103d ago·Positive
Trump wants to split the MMR vaccine. Experts say that's unlikely — and comes with consequences President Donald Trump's latest executive order calls for splitting the measles, mumps and rubella, or MMR, vaccine into three separate shots. But doctors and other experts say that effort has no scientific basis and is unlikely to get off the ground.
View source ↗
Earnings
Wed, Feb 3(in 2 months)
Consensus estimate $0.77 per share
Typical surprise +6.9% (median, so one quarter with a near-zero estimate can't distort it)
- Wed, Oct 28$1.47 vs $1.40beat
- Tue, Jul 28$1.36 vs $1.27beat
- Wed, Apr 29$1.24 vs $1.16beat
- Wed, Feb 4$0.68 vs $0.64beat
- Wed, Oct 29$1.48 vs $1.26beat
- Wed, Jul 30$1.23 vs $1.12beat
Estimates and results for GSK via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Congress trades
- Lisa C. McClainhouse · MI09 · disclosed Nov 24, 2025 (25d later)Sell$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Nov 24, 2025 (24d later)Sell$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Nov 24, 2025 (25d later)Buy$1,001 - $15,000
- Val Hoylehouse · OR04 · disclosed Oct 10, 2025 (17d later)Sell$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Sep 15, 2025 (42d later)Buy$1,001 - $15,000
- Val Hoylehouse · OR04 · disclosed Sep 12, 2025 (298d later)Buy$1,001 - $15,000
- Robert Aderholthouse · AL04 · disclosed Sep 11, 2025 (45d later)Sell$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (57d later)Buy$1,001 - $15,000
- Lisa C. McClainhouse · MI09 · disclosed Aug 13, 2025 (50d later)Sell$1,001 - $15,000
- Bruce Westermanhouse · AR04 · disclosed May 13, 2025 (22d later)Sell$1,001 - $15,000
- Bruce Westermanhouse · AR04 · disclosed Apr 17, 2025 (45d later)Buy$1,001 - $15,000
- Marjorie Taylor Greenehouse · GA14 · disclosed Nov 27, 2024 (2d later)Buy$1,001 - $15,000
- Thomas Hawley Tubervillesenate · AL · disclosed Nov 16, 2023 (31d later)Sell$1,001 - $15,000
- Daniel Goldmanhouse · NY10 · disclosed Aug 13, 2023 (34d later)Sell$15,001 - $50,000
- Thomas Hawley Tubervillesenate · AL · disclosed May 12, 2023 (39d later)Buy$1,001 - $15,000
- Thomas Hawley Tubervillesenate · AL · disclosed May 11, 2023 (38d later)Buy$1,001 - $15,000
- Virginia Ann Foxxhouse · NC05 · disclosed Apr 4, 2023 (34d later)Sell$50,001 - $100,000
- Virginia Ann Foxxhouse · NC05 · disclosed Sep 8, 2022 (29d later)Buy$15,001 - $50,000
- Virginia Ann Foxxhouse · NC05 · disclosed Sep 8, 2022 (34d later)Buy$15,001 - $50,000
- Virginia Ann Foxxhouse · NC05 · disclosed Sep 8, 2022 (23d later)Buy$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
